BOSTON, Nov. 21, 2018 /PRNewswire/ -- Proteostasis
Therapeutics, Inc. (NASDAQ: PTI), a clinical stage
biopharmaceutical company dedicated to the discovery and
development of groundbreaking therapies to treat cystic fibrosis
(CF) and other diseases caused by dysfunctional protein processing,
today announced today announced that Proteostasis management will
participate in the following upcoming investor conferences:
- The Piper Jaffray 30th Annual Healthcare Conference
on Wednesday, November 28, 2018 at
12:30 pm ET at the Lotte New York
Palace.
- The Citi 2018 Global Healthcare Conference on Thursday, December 6, 2018 at the Lotte New York
Palace.
A live audio webcast of the Piper Jaffray Conference
fireside chat will be available on the Investor Events page in the
Investors & Media section of the Company's
website, www.proteostasis.com. A replay of the webcast will be
available on the Company's website following the presentation.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage
biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional
protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team
focuses on identifying therapies that restore protein function. In
addition to its multiple programs in cystic fibrosis, Proteostasis
Therapeutics has formed a collaboration with Astellas Pharma, Inc.
to research and identify therapies targeting the Unfolded Protein
Response (UPR) pathway. For more information, visit
www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "aim," "may," "will," "expect,"
"anticipate," "estimate," "intend," and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Examples of forward-looking
statements made in this release include, without limitation,
statements regarding the potential of our proprietary double
combination therapy for the treatment of CF, the potential
benefit to patients of our proprietary double combination therapy,
expected presentations and expected timing of the initiation of,
patient enrollment in, data from, and the completion of, our
clinical studies and cohorts for our clinical programs.
Forward-looking statements made in this release involve substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by the forward-looking
statements, and we, therefore cannot assure you that our plans,
intentions, expectations or strategies will be attained or
achieved. Such risks and uncertainties include, without
limitation, the possibility final or future results from our drug
candidate trials (including, without limitation, longer duration
studies) do not achieve positive results or are materially and
negatively different from or not indicative of the preliminary
results reported by the Company (noting that these results are
based on a small number of patients and small data set),
uncertainties inherent in the execution and completion of clinical
trials (including, without limitation, the possibility that
FDA comments delay, change or do not permit trial
commencement, or intended label, or the FDA requires us
to run cohorts sequentially or conduct additional cohorts or
pre-clinical or clinical studies), in the enrollment of CF patients
in our clinical trials in a competitive clinical environment, in
the timing of availability of trial data, in the results of the
clinical trials, in possible adverse events from our trials, in the
actions of regulatory agencies, in the endorsement, if any, by
therapeutic development arms of CF patient advocacy groups (and the
maintenance thereof), and those set forth in our Quarterly Report
on Form 10-Q for the quarter ended June 30, 2018 and our
other SEC filings. We assume no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
CONTACTS:
Investors:
David Pitts
/ Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-to-participate-in-upcoming-investor-conferences-300753347.html
SOURCE Proteostasis Therapeutics, Inc.